Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Bimetallic Complexes for the Activation and Catalytic Functionalisation of Vinylic C-H Bonds (Bim-CH-Act)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: United Kingdom
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-06-01
End date: 2027-05-31
Duration (months): 24.0
Total project cost (EUR): 260347.92
EU funding (EUR): 260347.92
Participants: 1
Project status: SIGNED

The catalytic and selective functionalisation of C–H bonds of organic molecules is a key enabling technology that has the potential to contribute to the sustainable production of commodity chemicals. This proposal targets the selective catalytic functionalisation of vinylic C–H bonds of unactivated olefins (e.g. ethylene, propylene) with novel heterometallic complexes based on abundant and inexpensive elements (e.g. Fe, Al or Ga). Despite appearing simple, this transformation is unprecedented. With nearly all systems studied to date, competitive π-coordination of the olefin to the metal site inhibits catalytic C–H functionalisation. In this project, the cooperativity between two adjacent metals will be used to create new mechanistic pathways that circumvent this issue. The proposal is divided into three distinct work packages focussing on (i) the development of new heterometallic complexes, (ii) their application in stoichiometric vinylic C–H activation and (iii) establishment of catalytic turnover for C–H functionalisation of unactivated olefins. Ultimately the new understanding and new methodology will be applied to the production of vinyl-alkoxysilanes, high-demand and industrial relevant polymer building blocks, from C–H functionalisation of ethylene. Successful realisation of this proposal will provide the fellow with additional know-how in bimetallic chemistry, C–H activation, and catalysis, expanding his skill set beyond his expertise in organometallic and main group chemistry. Additional experience and training in aspects of leadership, teaching and management will complement the fellow’s education to a degree of professional maturity, making him highly competitive for independent funding and positions in academia.

Keywords: bimetallic chemistry vinylic c h activation main group ligand catalytic silylation
Dissecting a stepwise principle of cellular diversification to instruct regeneration in the enteric nervous system (divENSify)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Cell Biology, Development, Stem Cells and R egeneration
Panel description: For all organisms : Structure and function of the cell, cell -cell communication, embryogenesis, tissue differentiation, organogenesis, growth, development, evolution of development, organoids, stem cells, regeneration, therapeutic approaches
Countries involved: Sweden
Call: ERC CONSOLIDATOR GRANTS (ERC-2021-COG, 2021)
Start date: 2022-09-01
End date: 2027-08-31
Duration (months): 60.0
Total project cost (EUR): 1999981.0
EU funding (EUR): 1999981.0
Participants: 1
Project status: SIGNED

The enteric nervous system (ENS) contains a large range of neural subtypes that collectively controls essential gut functions independently of the central nervous system (CNS). Although the ENS is capable of forming new neurons following injury or inflammation, it fails to regenerate completely. My lab recently established a molecular classification of enteric neurons and discovered that they diversify through a conceptually new principle during development. Only two neuronal identities form during neurogenesis while all other classes emerge through subsequent differentiation at the postmitotic stage. This stepwise conversion process contrasts from the better understood CNS development where spatial patterning of stem cells predominates cell fate decisions. Dissecting the molecular basis for the sequential acquisition of cell identities in the ENS will advance our fundamental understanding of cell heterogeneity emergence. In divENSify we propose to push new frontiers in neuronal identity formation to facilitate constructive regeneration in the adult gut. Combining single cell RNA and chromatin profiling we will assess the role of pioneering transcription factors and competent cell states in each step of differentiation. We will dissect gene regulatory networks and identify key determinants using ultrasound-guided gene manipulation, a novel method we recently developed to target the otherwise inaccessible ENS in utero. We will determine how injury-induced adult neurogenesis correlates with developmental paradigms and leverage knowledge on latent potentials and intrinsic transcriptional regulators to engineer specific neuron types through viral gene manipulation in the adult gut. The proposed project will transform our comprehension of neuron identity formation and maintenance and provide proof-of-principle experiments that open for self-repair strategies to treat neurological gut disorders.

Keywords: enteric nervous system,single cell rna sequencing,neurogenesis,epigenetic sequencing,cell type specification
Macrocycles for Drug Discovery (MC4DD)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Doctoral Networks
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Germany,Sweden,Italy,Switzerland,Croatia,United Kingdom,Netherlands,Ukraine,Denmark
Call: MSCA Doctoral Networks 2023 (HORIZON-MSCA-2023-DN-01, 2023)
Start date: 2024-11-01
End date: 2028-10-31
Duration (months): 48.0
Total project cost (EUR): 3731634.51
EU funding (EUR): 3270780.0
Participants: 20
Project status: SIGNED

Better drugs are one of the most efficient and sustainable ways to improve health care, a key strategic orientation in Horizon Europe. New drug modalities such as macrocycles are expected to be a key enabling technology for this strategic perspective. The goal of MC4DD is to train the next generation of European medicinal chemists in a multidisciplinary environment to promote European drug discovery competitiveness, directly by advancing knowhow on macrocycles and long-term via the skills carried on by the researchers trained in the doctoral network.

Keywords: pharmacology,drug modalities,drug discovery and design
Bioorthogonal Iontronic Chemistry: Spatiotemporal Drug Release with Electronic Precision (Time2SWITCH)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Physical and Analytical Chemical Sciences
Panel description: Analytical chemistry, chemical theory, physical chemistry/chemical physics
Countries involved: Austria
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-09-01
End date: 2029-08-31
Duration (months): 60.0
Total project cost (EUR): 1496795.0
EU funding (EUR): 1496795.0
Participants: 1
Project status: SIGNED

I envision a new drug delivery system capable spatiotemporal release with electronic precision. This technology is based on; Biontronic Chemistry (BC) which combines Bioorthogonal Release (BR) and Iontronic transport to overcome the drawbacks of each individual technology and combine their unique advantages. An electronic ion pump (IP) will enable programable electrophoretic transport of chemical triggers without liquid flow or moving mechanical parts to initiate the ultrafast & selective bioorthogonal release (BR) of drugs at the target site to generate previously unobtainable dynamic concentration-time profiles. Hence, BC translates electrical stimuli, of arbitrary frequencies and amplitudes, into tailor-made bio-chemical concentration/time profiles. By incorporating surface release functionalities and orthogonal bioorthogonal chemistries I will further expand the concept and demonstrate choreographed cascade releases to afford individually programmable release of multiple compounds with distinct concentration/time profiles. We will map out this large parameter space using a combination of rational chemical design, computationally aided device physics and engineering, fluorescent model systems and finally evaluation in cell models. T2S will lay the foundation for new directions in science and offer unprecedented opportunities for various therapies wherein choreographed, spatiotemporal control of multiple drug release is key (e.g. cancer; nerve regeneration and aging). My hypothesis is that if we combine local drug delivery and chronotherapy, we can dramatically increase treatment efficacy and reduce (if not completely) eliminate side effects. My overarching goal is to create a Switch that elevates medicine to the 5th dimension (5D) thus paving the way towards a paradigm shift in drug delivery and our understanding/ability to manipulate biological-spacetime by delivering the right dose (1D) at the right place (3D) at the right time (1D).

Keywords: bioorthogonal reactions,click chemistry,iontronic devices,chronotherapy,bioelectronics
Integrated oxy-combustion solutions for flexible, bio-based combined heat and power: A Negative Emissions Technology for a net-zero Europe (BioNETzero)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Sustainable, secure and competitive energy supply
Action type: Research and Innovation actions
Countries involved: Norway,Spain,Denmark,Poland,France
Call: Development of near zero-emission biomass heat and/or CHP including carbon capture (HORIZON-CL5-2023-D3-02, 2023)
Start date: 2024-05-01
End date: 2027-04-30
Duration (months): 36.0
Total project cost (EUR): 3999782.5
EU funding (EUR): 3999782.5
Participants: 9
Project status: SIGNED

Combined Heat and Power (CHP) is a highly efficient method for co-generating electricity and heat. With biomass feedstocks, CHP can be considered a renewable source. The capture of CO2 from biomass CHP presents an opportunity for carbon removal, aiding Europe's journey toward negative emissions.Challenges, including supply logistics, feedstock sustainability, and competition with other renewables like wind and solar, must be overcome to achieve cost-effective, low-emission, and decarbonized CHP from solid biomass residues. Additionally, issues like feedstock handling, combustion efficiency, emissions (NOx, SOx, particles), and economic feasibility hinder market development. The BioNETzero project's objective is to significantly advance three oxy-combustion technologies (oxy-MILD, CLC, and oxy-CFB). The project addresses these technical challenges through real-world testing, modelling, and the development of precise digital tools. Comprehensive regional showcase studies conducted by BioNETzero encompass technological, social, environmental, and economic dimensions. These advancements seek synergies with oxygen supply solutions such as cryogenic methods, alignment with the hydrogen economy, and utilization of solid oxygen carriers. Integration with flue gas cleaning and CO2 conditioning processes facilitates carbon removal, enabling the realization of nearly zero-emission biomass heating and biomass CHP systems, including carbon capture. One of BioNETzero's advantages lies in its regional focus, recognizing that deployment obstacles often arise at local levels. The project will assess its suite of solutions in regions in transition across Europe, and propose novel solutions for next generation CHP plants.

Keywords: biomass residues,negative emissions technology,oxy combustion,flue gas cleaning
Understanding the impact of responses to climate change on children's political socialization (KIDSONCLIMATE)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Belgium
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-09-01
End date: 2027-08-31
Duration (months): 24.0
Total project cost (EUR): 216240.0
EU funding (EUR): 216240.0
Participants: 1
Project status: SIGNED

What does it mean to grow up learning about politics in a context marked by the climate crisis? What if your first awareness of a political issue was one that politicians seem unable to solve? KIDSONCLIMATE investigates how young teenagers’ awareness of the climate crisis, and the emotions it generates, might impact their (dis)engagement with politics at different levels (national, local, European). It uses existing quantitative data from the IEA International Civics and Citizenship Education Study (ICCS) along with innovative qualitative methodologies with 13-year-olds and their parents in two countries (Belgium and France) to ask: how do the emotions generated by the climate crisis impact young teens’ support for the political system they live in and their feelings of political belonging? What are the social, political, educational, and media factors that influence these emotions? At a time when the effects of the climate crisis are ever more visible and dramatic, and many young people are turning away from institutional politics, or towards populism and the far right, we urgently need to understand how the emotions resulting from this context might impact how young people feel about their political system and their place within it.

Keywords: political socialization,emotions and politics,youth and politics,political attitudes,environmental education,generational renewal,climate change
Evolutionary Arms Races Shaping the Germline Epigenome (EvoEpi)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Environmental B iology, Ecology  and E volution
Panel description: For all organisms : Ecology, biodiversity, environmental change , evolutionary biology, behavioural ecology, microbial ecology , marine biology, ecophysiology, theoretical developments and mod elling
Countries involved: France
Call: ERC CONSOLIDATOR GRANTS (ERC-2024-COG, 2024)
Start date: 2025-04-01
End date: 2030-03-31
Duration (months): 60.0
Total project cost (EUR): 1996223.0
EU funding (EUR): 1996223.0
Participants: 1
Project status: SIGNED

Germline chromatin pathways are key to the stable inheritance of genetic and epigenetic information. They also participate in intense evolutionary battles between genetic entities with opposite incentives during reproduction. These include conflicts between transposons and host genomes, between chromosomes during meiosis, and between maternal and paternal epigenomes. Such genetic conflicts are predicted to drive evolutionary arms races leading to rapid genetic and epigenetic innovations. Contrary to current dogmas focusing on conserved features, my research program explicitly tackles the functional consequences of epigenome rapid evolution during mammalian reproduction and disease, including in humans. With the support of the ERC, we want to harvest this unique perspective on the germline epigenome to explore novel inheritance paradigms: (1) Using mouse models, we discovered that rapidly evolving short histone H2A variants function in a novel imprinting-like conflict during reproduction. We will identify the mechanisms underlying these functions combining epigenome profiling with evolution-guided hypothesis testing in vivo. We then seek to explore their contributions to reproductive barriers using functional genetics across mouse sub-species. (2) Using in-depth phylogenomics and selection analyses, we uncovered novel signatures of functional diversification in rodent and primate chromatin remodelling enzymes. We propose to systematically identify these innovations across mammalian germline chromatin pathways. (3) To study the chromatin consequences of these innovations, we designed a surrogate system in human and mouse cells for comparative epigenome profiling. We will use this approach to uncover the breadth of epigenome regulatory mechanisms shaped by potential genetic conflicts in vivo. In sum, this proposal interfaces our unique expertise in epigenomics and evolution to transform our current understanding of epigenome regulation and its impact on reproduction.

Keywords: genetic conflicts,positive selection,histones,chromatin pathways,germ cells,speciation
Massively scaling-up protein-protein interaction mutagenesis. (DeepScalePPIs)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-04-01
End date: 2027-03-31
Duration (months): 24.0
Total project cost (EUR): 194074.56
EU funding (EUR): 194074.56
Participants: 1
Project status: SIGNED

Understanding, predicting and engineering protein-protein interaction (PPI) affinity and specificity is a key problem in molecular biology. In particular, we do not know how sequence-to-affinity encoding works at a quantitative and mechanistic level and we cannot predict and engineer the effects of mutations on PPIs. To tackle this problem, we need to generate large amounts of quantitative biophysical measurements. Until now this was not possible due to the low throughput of classic biophysics techniques. Here we propose to expand high-throughput deep mutational scanning (DMS) methodology to quantify the effects of tens of millions of mutations on hundreds of PPIs. To generate a dataset of sufficient size and diversity to train models to predict changes in binding affinity from sequence, we will perform combinatorial trans mutagenesis by combining single mutants in the interaction interface of each partner of a given PPI and quantify the change in binding using a highly-validated protein complementation assay (PCA). To establish the platform, we will first focus on mutating PPIs of the KRAS oncoprotein. We will then scale up this approach to mutate at least one hundred structurally diverse PPIs. The resulting dataset will be of unprecedented size and standardisation, serving as a landmark reference dataset for us and others to train and evaluate models to predict the effects of mutations on interaction affinity. These data and models should transform our ability to understand clinical variants affecting PPIs and allow us to better understand, drug and engineer PPIs critical for medicine and biotechnology. “DeepScalePPIs” will be supervised by Prof. Ben Lehner (CRG, Barcelona), whose group has pioneered the use of deep mutagenesis to understand protein structures, dynamics and interactions. In this unique environment I will be able to learn and combine knowledge from different fields s as genomics, systems biology, biophysics and computational biology.

Keywords: biophysics,dms,deep mutagenesis,high throughput,protein protein interactions,genomics,computational biology,machine learning,
NCPS NETwork for the GREEN transition in climate, energy and mobility (GREENET)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Climate, Energy and Mobility
Theme: Energy
Destination: Cross-sectoral solutions for the climate transition
Action type: Coordination and support actions
Countries involved: Italy,Belgium,Cyprus,Germany,Estonia,Greece,Spain,Netherlands,Poland,Türkiye,Portugal,Iceland,Ireland,Luxembourg,France,Finland,Czechia,United Kingdom,Malta
Call: Fostering cooperation between Horizon Europe cluster 5 National Contact Points (NCPs) (HORIZON-CL5-2021-D2-01, 2021)
Start date: 2022-07-01
End date: 2027-12-31
Duration (months): 66.0
Total project cost (EUR): 3250901.25
EU funding (EUR): 3250901.25
Participants: 19
Project status: SIGNED

The overall aim of GREENET is to improve the professionalisation and skills of the Cluster 5 (CL5) National Contact Points (NCPs) across Europe, simplifying applicants’ access to Horizon Europe (HE) calls and raising the average quality of submitted proposals. Starting from the assumption that the NCP role is crucial in order to raise the participation in HE in terms of both quality and quantity, the GREENET overall concept is that the CL5 NCP community requires knowledge, skills, competences and a proven comprehensive suite of tools to convey a message in a multicultural and multi-disciplinary environment such as CL5 and to effectively support its broad based constituency. Therefore, the project is based on three pillars: (i) NCPs capacity building and competence development, (ii) development of targeted and high quality services (events and tools) for CL5 applicants and stakeholders , (iii) CL5 community building and general mainstreaming of CL5 NCPs in Horizon Europe.

Keywords: competence development,capacity building,cl5 ncps collaboration,cl5 ncps community,stakeholders engagement,awareness raising,newcomer applicants,matchmaking,synergies with relevant actors
MAP, JOIN AND DRIVE EUROPEAN ACTIVITIES FOR ADVANCED THERAPY MEDICINAL PRODUCT DEVELOPMENT AND IMPLEMENTATION FOR PATIENT AND SOCIETY BENEFIT (JOIN4ATMP)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Maintaining an innovative, sustainable and globally competitive health industry
Action type: Coordination and support actions
Countries involved: Germany,Italy,Denmark,France,Netherlands,Sweden,Belgium,Austria,Spain
Call: Mapping the hurdles for the clinical applications of Advanced Therapy Medicinal Products (ATMPs) (HORIZON-HLTH-2023-IND-06, 2023)
Start date: 2024-01-01
End date: 2026-12-31
Duration (months): 36.0
Total project cost (EUR): 3354958.75
EU funding (EUR): 2999958.75
Participants: 14
Project status: SIGNED

Advanced Therapy Medicinal Products (ATMPs) are medicines based on genes, cells and tissues for human use. They can provide patients novel treatment alternatives to significantly improve or even cure diseases that currently have no or inadequate standard-of-care options. However, significant challenges remain for the scientific, clinical and patient communities as well as commercial entities and regulatory, policy-making and technology-assessing bodies. The JOIN4ATMP consortium unites international experts and stakeholders with the mission to accelerate and de-risk European ATMP development and ensure wide-spread equitable ATMP access for patients with common diseases, rare non-cancer diseases and rare cancers in Europe. It brings together all members of the European University Hospital Alliance with the existing EU-funded T2EVOLVE and RESTORE networks, and with active support from industry partners and patient representatives as our 14 core partners. The core partners are joined by supporting partners active in ATMP development, production, application and regulation. Our team will use real-world data and experiences to achieve the most rapid and holistic map of current hurdles and the best way to improve support and regulation of ATMP development and use in the EU and associated countries. The JOIN4ATMP end-product will be a state-of-the-art information package circumscribing (i) currently existing and potential future hurdles preventing rapid and streamlined ATMP development and clinical translation and (ii) a defined set of recommendations to overcome these hurdles in a manner guaranteeing equitable access for patients throughout Europe. We are committed to the long-term operation of our network and take steps to assure its sustainability in order to inform and coordinate activities in Europe for the ATMP field, which will only gain in importance with the advance of personalized medicine in the future.

Keywords: atmps development regulatory approval commercialization access for patients